873947-63-8 Usage
Molecular structure
The compound consists of a piperidine ring, a carboxylic acid group, a nitro group, a phenylmethyl ester, and a phenyl ring.
Functional groups
The main functional groups present in the compound are a piperidine carboxylic acid, a nitro group, and a phenylmethyl ester.
Trifluoromethyl group
The compound contains a trifluoromethyl group, which is known for its high electronegativity and can influence the compound's reactivity and properties.
Stereochemistry
The "2S" designation indicates the orientation of certain atoms in the compound, which can affect its biological activity and interactions with other molecules.
Potential applications
The compound may have potential applications in pharmaceuticals and organic synthesis, but further investigation is needed to determine its specific uses and properties.
Complexity
The compound is a complex molecule with multiple functional groups and stereochemistry, which can influence its reactivity, properties, and potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 873947-63-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,3,9,4 and 7 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 873947-63:
(8*8)+(7*7)+(6*3)+(5*9)+(4*4)+(3*7)+(2*6)+(1*3)=228
228 % 10 = 8
So 873947-63-8 is a valid CAS Registry Number.
873947-63-8Relevant academic research and scientific papers
PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS
-
Page/Page column 12, (2010/04/30)
This application discloses a novel process to synthesize 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds, which may be used, for example, as NK-1 inhibitor compounds in pharmaceutical preparations.
NK1 ANTAGONISTS
-
Page/Page column 83-84, (2010/02/15)
A compound having the general structure shown in Formula (I) or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symp
BRIDGED RING NK1 ANTAGONISTS
-
Page/Page column 81, (2010/11/08)
A compound having the general structure shown in Formula (I): or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or di
